|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,286.00 INR | +0.10% |
|
+3.56% | -1.67% |
| 01/04 | Avendus Spark Upgrades Divi's Laboratories to Reduce from Sell, Price Target is INR5,840 | MT |
| 12/02 | Jefferies Adjusts Divi's Laboratories' Price Target to INR8,100 From INR8,000, Keeps at Buy | MT |
Business description: Divi's Laboratories Limited
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Number of employees: 10,542
Sales by Activity: Divi's Laboratories Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients | 6.97TCr | 8.96TCr | 7.77TCr | 7.84TCr | 9.36TCr |
Geographical breakdown of sales: Divi's Laboratories Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Other Countries | 4.68TCr | 5.92TCr | 4.95TCr | 4.79TCr | 5.04TCr |
Switzerland | - | - | - | 1.02TCr | 1.91TCr |
USA | 1.38TCr | 2TCr | 1.85TCr | 1.05TCr | 1.31TCr |
India | 912.36Cr | 1.04TCr | 975.58Cr | 984Cr | 1.11TCr |
Executive Committee: Divi's Laboratories Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04/01/2020 | |
| Chief Executive Officer | 75 | 26/11/2009 | |
| Director of Finance/CFO | 65 | 01/08/2025 | |
Srinivasa Rao P.
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/11/1990 |
K. Subba Rao
ADM | Chief Administrative Officer | 62 | - |
Composition of the Board of Directors: Divi's Laboratories Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 26/11/2009 | |
| Director/Board Member | 48 | 26/11/2009 | |
| Director/Board Member | 68 | 01/10/1994 | |
| Director/Board Member | 44 | 27/06/2017 | |
S. Devendra Rao
BRD | Director/Board Member | 64 | 10/02/2024 |
| Director/Board Member | 65 | 25/05/2024 | |
| Chairman | - | 01/04/2020 | |
Ganapaty Seru
BRD | Director/Board Member | 73 | 22/07/2017 |
Sunaina Singh
BRD | Director/Board Member | 70 | 28/03/2019 |
| Director/Board Member | 71 | 04/01/2020 |
Company details: Divi's Laboratories Limited
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.10% | +3.56% | +11.45% | +96.25% | 1.79TCr | |
| -1.83% | -2.85% | +7.51% | +140.93% | 82TCr | |
| -1.96% | -4.96% | +43.62% | +38.26% | 56TCr | |
| +0.69% | -0.65% | +18.57% | +26.82% | 36TCr | |
| +2.07% | +0.88% | +25.20% | +15.27% | 33TCr | |
| -2.62% | -2.86% | +43.82% | +21.23% | 31TCr | |
| -3.88% | -6.32% | +44.31% | -1.41% | 29TCr | |
| -1.79% | -3.75% | +28.10% | +31.71% | 29TCr | |
| -1.51% | -1.42% | +24.37% | +41.65% | 19TCr | |
| -4.19% | +3.71% | -41.34% | -55.81% | 18TCr | |
| Average | -1.08% | +0.37% | +20.56% | +35.49% | 33.49TCr | |
| Weighted average by Cap. | -0.67% | -0.56% | +23.14% | +49.84% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DIVISLAB Stock
- Company Divi's Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition